Philochem to license worldwide rights to OncoACP3, a novel radiopharmaceutical therapeutic and diagnostic agent targeting prostate cancer to RayzeBio: Otelfingen, Switzerland Thur ...

Bristol MyersBMY announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis ...

US chemical output slows, National Resilience consolidates operations, AstraZeneca partners with a Chinese firm, and more ...

In accordance with the agreement, Philochem will get $350 million up front and could get up to $1 billion in milestone ...

Bristol Myers Squibb has expanded its push into radiopharmaceuticals by licensing a prostate cancer therapy developed by Swiss biotech Philochem in a deal that includes an upfront payment of $350 ...

Bristol Myers Squibb has expanded its push into radiopharma by licensing a prostate cancer therapy developed by Philochem for $350m upfront.

Bristol Myers Squibb has declared a quarterly dividend of $0.62 per share, maintaining its impressive 55-year streak of ...

Bristol Myers' Sotyktu, a TYK2 inhibitor already approved for psoriasis, scored a win in a Phase III trial for psoriatic ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology ...

JHVEPhoto/iStock Editorial via Getty Images Bristol Myers Squibb (NYSE:BMY) said that an analysis of data from a phase 2 cohort of patients with marginal zone lymphoma showed that treatment with ...